Compare BOC & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | FBRX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.4M | 487.2M |
| IPO Year | 2010 | 2017 |
| Metric | BOC | FBRX |
|---|---|---|
| Price | $12.07 | $32.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | 124.8K | ★ 375.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $114,376,348.00 | $36,000.00 |
| Revenue This Year | $4.46 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.64 | N/A |
| 52 Week Low | $11.03 | $4.91 |
| 52 Week High | $15.72 | $35.80 |
| Indicator | BOC | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 61.85 |
| Support Level | $12.01 | $26.67 |
| Resistance Level | $12.87 | $35.62 |
| Average True Range (ATR) | 0.37 | 3.65 |
| MACD | 0.03 | 0.94 |
| Stochastic Oscillator | 60.86 | 75.41 |
Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.